
First at-home test to screen for cervical cancer approved by FDA
The Teal Wand, which will be available for those age 25 to 65 at average risk, tests for human papillomavirus, or HPV, a virus that causes most cervical cancers.
Teal Health CEO Kara Egan didn't say how much the test would cost. Egan anticipates the test will be covered by insurance.
They will first be available in California in June and then expand nationwide.
Until now, the only way to screen for cervical cancer was in a doctor's office during a pelvic exam.
'As a mom and a woman, I get how easy it is to put your own health last,' Egan said in a news release. 'That's why this FDA approval means so much; it's not just about an innovative new product, it's about finally giving women an option that actually makes sense for their lives -- something that can be done quickly and comfortably at home. Because when we make care easier to get, we help women stay healthy, for themselves and for the people who rely on them every day.'
Because of the invasive aspect, the company found 1 in 4 women in the United States are behind in testing.
Dr. Emeline Aviki, a gynecologic-oncologist at New York University Langone Health, who worked on initial studies, told CNBC: 'It's not a fun exam and it's the easiest thing to cancel.'
She worked on early studies to validate the new test.
In a Teal Health study, 86% of participants thought they would more likely stay up-to-date with cervical cancer screening if they could do it at home. And 94% said they would prefer to self-collect at home if it were accurate.
In the new vaginal swab, a speculum is used and samples of cells are collected from the cervix.
Last year, the FDA approved a similar swab, also performed by patients themselves, that's collected in a doctor's office.
'What's different about this new indication is that this sample can be collected at home and not in a medical setting,' Dr. George Sawaya, a gynecologist at University of California San Francisco Health, told CNBC. You have to logically believe that would increase access if people's main barrier was getting to a medical setting.'
Patients can order the test kit after a telehealth appointment with a doctor. The swab is then mailed to a lab for analysis.
The product initially must be prescribed by one of Teal Health's virtual providers.
If there is a positive test, women may need additional tests in a doctor's office.
The American Cancer Society estimates that 13,360 women will be diagnosed with cervical cancer this year and about 4,320 women will die. 'Cervical cancer incidence rates decreased by more than half from the mid-1970s to the mid-2000s because of widespread screening uptake,' ACA said.
Cervical cancer mortality rates also dropped by more than half since the mid-1970s.
The study found the test detects cervical precancer 96% of the time.
'As a Principal Investigator in the SELF-CERV trial, I saw firsthand how receptive and excited women were to use the Teal Wand,' Dr. Christine Conageski, associate professor, OB-GYN and director of the Complex Dysplasia Clinic at the University of Colorado, said in the company's news release. 'Cervical cancer is largely preventable, yet screening rates in the U.S. continue to lag, and the FDA approval of this at-home Teal Wand self-collection device is a critical step forward. It offers an evidence-based way to expand access without compromising accuracy.'
She noted women must do more than be tested.
'But access is only part of the solution,' she said. 'Comprehensive screening must go hand in hand with structured, reliable follow-up.'
Last year, researchers found a new urine test might help doctors more easily screen for cervical cancer. The test looks for proteins generated by a type of cancer-causing human papillomavirus, HPV 16.
Copyright 2025 UPI News Corporation. All Rights Reserved.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California
Unlocking a new geography, making Neuraceq® available to more patients BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and distribution network for Neuraceq® (florbetaben F-18 injection) in Southern California. This expansion increases access to the broader Southern California area, including San Diego, extending availability of Neuraceq® to imaging centers, physicians, and patients with cognitive impairment. The first dose from a newly-equipped site in Los Angeles was provided on August 13, 2025. Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs. This expansion reflects LMI's ongoing commitment to advancing diagnostic access and improving outcomes for patients affected by Alzheimer's disease in California. "At LMI, we are focused on expanding geographical access to Neuraceq® for patients and physicians involved in the evaluation of Alzheimer's disease. As the adoption of anti-amyloid therapies continues to grow, the demand for reliable amyloid PET imaging is increasing in parallel. Launching Neuraceq® from Los Angeles is a key milestone in meeting this rising demand. It reflects our ongoing dedication to delivering timely, high-quality diagnostic solutions that align with the evolving needs of neurologists and patients," said Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC of LMI, a Lantheus company. About Neuraceq® (florbetaben 18F) Indications and Use NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products. CONTRAINDICATIONS: None WARNINGS AND PRECAUTIONS: Risk for Image Misinterpretation and other Errors: NEURACEQ Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. [see Section 5.1 of the full prescribing information] Radiation Risk: NEURACEQ, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration in the full prescribing information]. ADVERSE REACTIONS: The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/application site erythema (1.7%), and injection site irritation (1.1%). For more information please visit: About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI), a Lantheus company, is dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit About LantheusLantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit ContactsInvestor Relations: Mark KinarneyVice President, Investor Relations978-671-8842ir@ Media: Melissa DownsExecutive Director, External Communications646-975-2533media@ View original content to download multimedia: SOURCE Life Molecular Imaging
Yahoo
an hour ago
- Yahoo
Americans' faith in food safety plummets
Over the past several months, the federal government has made extensive cuts to instrumental food health and safety organizations like the Food and Drug Administration (FDA), the U.S. Department of Agriculture (USDA), and the Center for Disease Control. And now, Gallup polling released this week says American confidence in the government to ensure food safety is at a new low. Shocker. Only 53% of Americans say they have a 'great deal' or 'fair amount' of confidence in food safety. This number has been dropping since 2006, however, there was a sharp decline starting in 2019. Despite this, 84% of Americans still report that their diet is at least 'somewhat healthy,' a number that has stayed consistent since Gallup started this reporting in 2001, but there hasn't been much — if any — increase in how many people are paying attention to nutrition labels and food warnings. Something that has become increasingly necessary as new food recalls are being announced almost daily. The USDA and FDA release public notices when they become aware of a recall, however, some of these notices aren't released until weeks or months after a contamination was reported. These recalls aren't always the easiest to find, sometimes they're hiding in the FDA Enforcement Report, which is completely different from the Recall, Market Withdrawals, & Safety Alerts Data Base. For example, in this week's enforcement report there are six ongoing recalls from the same company (King Cheesecake Company Inc.) because various products included pecans that were potentially contaminated with salmonella. This is listed as a Class I recall, the most serious from the FDA. The recall was initiated on July 18, but not classified by the FDA until August 7. To make matters worse, there is no listed press release for the recall even though it affects products and consumers in six different states including Alabama, Texas, Florida, Louisiana, Oklahoma and Illinois. Despite the cuts, officials have maintained that the number of inspectors and other food regulators will not change. Other experts are saying these cuts are a massive threat to public health and safety and could lead to dangerous disease outbreaks and consistent food recalls. Who's to say which is true, but it's clear the majority of Americans aren't confident in our food systems right now. All in the name of making America healthy again — apparently. The post Americans' faith in food safety plummets appeared first on Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
Hologic HOLX is a leading name in the cytology space, with its Cytology business, part of its Diagnostics franchise, primarily focusing on screening for cervical cancer. The company has pioneered the first FDA-approved liquid-based cytology test — the ThinPrep Pap test — and the first FDA-approved mRNA-based HPV test — the Aptima HPV Assay. Co-testing — combining a Pap test with an HPV test — is the most sensitive testing option for cervical cancer screening compared to either test used alone. While this business of Hologic has historically been a flattish to single-digit grower, the company has continued to invest in it, like the 2024 launch of the Genius digital cytology system. It was a significant introduction, marking the only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. HOLX management noted that if not for the sales headwinds in China, Cytology would have grown in low single digits in the second quarter of fiscal 2025, driven by the rollout of its Genius digital diagnostics system, instead of reporting a 2.2% decline. With more labs around the world implementing this in-house innovation, Hologic has received strong positive feedback. Genius replaces the traditional manual review of path slides, which was previously conducted on glass under a microscope, by capturing a digital image of the slide, which can be reviewed remotely from anywhere in the customer's network on the company's review station. These workflow advantages not only address their growing labor shortages but also enable cervical cancer screening in regions with limited infrastructure. Because the Genius system requires an overhaul of the traditional pet screening workflow, Hologic expects the full rollout to be a multi-year process, serving as a growth driver for the next several quarters. HOLX's Peers in Cervical Cancer Screening Quest Diagnostics DGX offers a complete menu of solutions for screening and diagnosing cervical cancer. In April this year, DGX introduced a new solution aimed at expanding access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer. With this new offering, physicians can offer patients the option to collect their specimen for HPV screening in a physician's office or other healthcare setting. Quest Diagnostics' latest test uses the FDA-cleared HPV self-collection solution from Roche, approved for use with Roche Holding AG's RHHBY cobas HPV test in May 2024. Roche's cervical cancer portfolio includes three clinically validated tests to help identify women at risk and improve the detection of high-grade disease in a single round of screening. The cobas HPV test is the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for all cervical screening indications — primary screening, ASC-US triage and co-testing. The CINtec PLUS Cytology test is the only FDA-approved triage test that uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. Roche's CINtec Histology test uses advanced p16 biomarker technology to confirm cervical lesions due to transforming HPV infections. HOLX Stock Performance, Valuation and Estimates In the past six months, Hologic shares have risen 5.2% against the industry's 11.9% fall. Image Source: Zacks Investment Research Hologic is trading at a forward three-year price-to-earnings of 15.23X, lower than the industry average of 28.67X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research Consensus estimates for Hologic's fiscal 2025 earnings are showing a mixed trend. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research